Sign In
Buy AUPH
$17.88
+0.350 (+2.00%)
At Close: Jun 23, 2026
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
08:11am, Tuesday, 23'rd Jun 2026
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
07:57am, Sunday, 07'th Jun 2026
814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share. The purchase represents 6.66% of Kevin Tang's total
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow
08:33am, Thursday, 04'th Jun 2026
Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue g
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
07:00am, Thursday, 04'th Jun 2026
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death.
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
01:22pm, Wednesday, 03'rd Jun 2026
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
08:30am, Tuesday, 19'th May 2026
Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ:
Parabolic AI rally has bulls eyeing a comeback for this one-time meme metal trade
02:49pm, Monday, 11'th May 2026
Silver prices surged 7% Monday to the highest since March.
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
12:16pm, Thursday, 07'th May 2026
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.
Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Cronos Group (NASDAQ:CRON) Financial Comparison
01:12am, Monday, 27'th Apr 2026
Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Cronos Group (NASDAQ: CRON - Get Free Report) are both medical companies, but which is the better investment? We will compare the two compa
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of “Hold” by Analysts
02:21am, Monday, 06'th Apr 2026
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH - Get Free Report) (TSE: AUP) has earned an average recommendation of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings r
SG Americas Securities LLC Grows Position in Aurinia Pharmaceuticals Inc $AUPH
04:45am, Sunday, 05'th Apr 2026
SG Americas Securities LLC raised its holdings in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) (TSE: AUP) by 69.6% in the undefined quarter, according to its most recent Form 13F filing with the Securit
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
08:00am, Monday, 30'th Mar 2026
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance
04:15pm, Friday, 27'th Mar 2026
Aurinia Pharmaceuticals has undergone a major management overhaul, with fund manager and activist investor Kevin Tang appointed as the CEO. AUPH's COO and CFO have also been replaced. Lupkynis's net p
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition
11:00am, Monday, 23'rd Mar 2026
CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“
